SET and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, the importance of the SET/PP2A interplay in cancer has been recently investigated in chronic myelogenous leukaemia in which a SET-mediated inhibition of PP2A phosphatase activity is distinctively occurring in patients with blast crisis CML (Neviani et al, 2005).